28509526|t|Paraoxonases and psoriasis: negative imbalance of anti--oxidant endogenous mechanisms
28509526|a|Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress. In the present study, we investigated PON gene expression in psoriasis and in cutaneous oxidative stress. The study population included 10 patients affected by moderate -to- severe plaque psoriasis and 15 healthy donors who have undergone to plastic surgery, were used as control. Skin punch biopsies of lesional and non lesional psoriatic skin were performed for analysis of PON2 and PON3 gene expression. In addition, oxidation assays in ex vivo full-thickness healthy skin organ cultures were performed. No significant differences were observed between PON2 and PON3 gene expression in psoriatic lesional and non lesional skin compared with healthy controls. H2O2 treatment induced a significant decrease of PON2 and PON3 expression in ex vivo full-thickness healthy skin organ cultures; conversely the pre-treatment of samples with the anti-oxidant reagent N-acetyl-L-cysteine (NAC) induced a significant increase. Interestingly, no significant alterations were reported for PON2 and PON3 expression in ex vivo full-thickness healthy skin organ cultures stimulated with IL-17. Taken together our findings have revealed that a strong pro-oxidative activity is not effectively countered by anti-oxidant endogenous mechanisms both in psoriatic skin and in ex vivo experimental model.
28509526	0	12	Paraoxonases	T116,T126	C0052451
28509526	17	26	psoriasis	T047	C0033860
28509526	28	36	negative	T033	C0205160
28509526	37	46	imbalance	T184	C1397014
28509526	50	63	anti--oxidant	T121	C0003402
28509526	64	74	endogenous	T169	C0205227
28509526	75	85	mechanisms	T044	C0678659
28509526	119	128	psoriasis	T047	C0033860
28509526	129	137	patients	T101	C0030705
28509526	147	157	exposed to	T080	C0332157
28509526	158	182	lipoprotein peroxidation	T044	C0023775
28509526	192	200	decrease	T081	C0547047
28509526	208	216	activity	T044	C2257843
28509526	220	238	paraoxonase (PON)1	T116,T126	C1121571
28509526	243	255	anti-oxidant	T121	C0003402
28509526	260	277	anti-inflammatory	T121	C0003209
28509526	278	284	enzyme	T116,T126	C0014442
28509526	319	330	malfunction	T169	C0231174
28509526	338	357	anti-oxidant system	T121	C0003402
28509526	365	374	increased	T081	C0205217
28509526	375	385	production	T038	C3714634
28509526	389	412	reactive oxygen species	T123,T196	C0162772
28509526	419	425	immune	T169	C0439662
28509526	426	438	inflammatory	T169	C0333348
28509526	439	445	events	T051	C0441471
28509526	452	458	result	T169	C1274040
28509526	462	473	progressive	T169	C0205329
28509526	474	483	skin cell	T025	C0814995
28509526	484	490	damage	T049	C0599732
28509526	494	502	patients	T101	C0030705
28509526	508	517	psoriasis	T047	C0033860
28509526	523	526	PON	T116,T126	C0052451
28509526	527	541	protein family	T116,T123	C1335532
28509526	553	557	PON1	T116,T126	C1257646
28509526	559	563	PON2	T116,T126	C0755726
28509526	568	572	PON3	T116,T126	C1447656
28509526	603	613	endogenous	T169	C0205227
28509526	614	632	defense mechanisms	T041	C0011142
28509526	641	657	oxidative stress	T049	C0242606
28509526	674	679	study	T062	C2603343
28509526	684	696	investigated	T169	C1292732
28509526	697	705	PON gene	T028	C0017337
28509526	706	716	expression	T045	C0017262
28509526	720	729	psoriasis	T047	C0033860
28509526	737	746	cutaneous	T082	C0221912
28509526	747	763	oxidative stress	T049	C0242606
28509526	769	774	study	T062	C2603343
28509526	775	785	population	T098	C1257890
28509526	798	806	patients	T101	C0030705
28509526	807	815	affected	T169	C0392760
28509526	819	827	moderate	T080	C0205081
28509526	833	839	severe	T080	C0205082
28509526	840	856	plaque psoriasis	T047	C0033860
28509526	864	871	healthy	T080	C3898900
28509526	872	878	donors	T098	C0013018
28509526	901	916	plastic surgery	T061	C0677616
28509526	931	938	control	T096	C0009932
28509526	940	959	Skin punch biopsies	T060	C0191321
28509526	963	971	lesional	T022	C1123023
28509526	976	1003	non lesional psoriatic skin	T022	C1123023
28509526	1023	1031	analysis	T062	C0936012
28509526	1035	1039	PON2	T028	C1418755
28509526	1044	1048	PON3	T028	C1418756
28509526	1049	1064	gene expression	T045	C0017262
28509526	1079	1088	oxidation	T044	C0030011
28509526	1089	1095	assays	T059	C0005507
28509526	1099	1106	ex vivo	T169	C2348480
28509526	1107	1121	full-thickness	T081	C0439809
28509526	1122	1129	healthy	T080	C3898900
28509526	1130	1134	skin	T022	C1123023
28509526	1135	1149	organ cultures	T059	C0029205
28509526	1155	1164	performed	T169	C0884358
28509526	1166	1192	No significant differences	T033	C3842396
28509526	1215	1219	PON2	T028	C1418755
28509526	1224	1228	PON3	T028	C1418756
28509526	1229	1244	gene expression	T045	C0017262
28509526	1248	1266	psoriatic lesional	T022	C1123023
28509526	1271	1288	non lesional skin	T022	C1123023
28509526	1289	1297	compared	T052	C1707455
28509526	1303	1319	healthy controls	T080	C2986479
28509526	1321	1325	H2O2	T121,T130,T197	C0020281
28509526	1326	1335	treatment	T169	C1522326
28509526	1336	1343	induced	T169	C0205263
28509526	1358	1366	decrease	T081	C0547047
28509526	1370	1374	PON2	T028	C1418755
28509526	1379	1383	PON3	T028	C1418756
28509526	1384	1394	expression	T045	C0017262
28509526	1398	1405	ex vivo	T169	C2348480
28509526	1406	1420	full-thickness	T081	C0439809
28509526	1421	1428	healthy	T080	C3898900
28509526	1429	1433	skin	T022	C1123023
28509526	1434	1448	organ cultures	T059	C0029205
28509526	1465	1478	pre-treatment	T079	C2709094
28509526	1482	1489	samples	T167	C0370003
28509526	1499	1519	anti-oxidant reagent	T121	C0003402
28509526	1520	1539	N-acetyl-L-cysteine	T116,T121	C0001047
28509526	1541	1544	NAC	T116,T121	C0001047
28509526	1546	1553	induced	T169	C0205263
28509526	1568	1576	increase	T169	C0442805
28509526	1593	1607	no significant	T033	C3694175
28509526	1608	1619	alterations	T169	C0392747
28509526	1638	1642	PON2	T028	C1418755
28509526	1647	1651	PON3	T028	C1418756
28509526	1652	1662	expression	T045	C0017262
28509526	1666	1673	ex vivo	T169	C2348480
28509526	1674	1688	full-thickness	T081	C0439809
28509526	1689	1696	healthy	T080	C3898900
28509526	1697	1701	skin	T022	C1123023
28509526	1702	1716	organ cultures	T059	C0029205
28509526	1717	1727	stimulated	T042	C1254358
28509526	1733	1738	IL-17	T116,T129	C0384648
28509526	1759	1767	findings	T033	C0243095
28509526	1789	1795	strong	T080	C0442821
28509526	1796	1818	pro-oxidative activity	T044	C2266999
28509526	1851	1863	anti-oxidant	T121	C0003402
28509526	1864	1874	endogenous	T169	C0205227
28509526	1875	1885	mechanisms	T044	C0678659
28509526	1894	1903	psoriatic	T047	C0033860
28509526	1904	1908	skin	T022	C1123023
28509526	1916	1923	ex vivo	T169	C2348480
28509526	1924	1942	experimental model	T170	C0086272